Biotech startups opt out of AI for drug discovery, say STAT

The latest STAT AI Prognosis newsletter notes that a number of biotech startups are deliberately avoiding artificial intelligence in their drug discovery programs.

These companies argue that AI may have greater impact elsewhere in the development pipeline and that traditional methods remain more reliable for finding new molecules.

The piece appears in a subscription‑only edition of STAT+, which also includes unrelated commentary about a viral video and subscription details.